U.S., April 16 -- ClinicalTrials.gov registry received information related to the study (NCT07532213) titled 'A Study to Assess Real-world Outcomes for Long-Term Use of Guselkumab' on April 08.
Brief Summary: The purpose of this study is to evaluate how long guselkumab remains in participants with moderate to severe crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are Inflammatory bowel disease, a group of inflammatory conditions of the colon and small intestine.
Study Start Date: April 23
Study Type: OBSERVATIONAL
Condition:
Inflammatory Bowel Disease
Colitis, Ulcerative
Crohn Disease
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Janssen-Cilag A.G., Switzerland
Disclaimer: Curated by HT Syndication...